Xilio Therapeutics (XLO) EPS (Basic) Growth (1y) (2021 - 2026)
Powered by 
Analysis
Xilio Therapeutics (XLO) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -84.77% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Xilio Therapeutics | 174.55 Mn | 38.51 Mn | - | 91.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.37% |
| Mar 31, 2026 | 66.75% |
| Dec 31, 2025 | 60.29% |
| Sep 30, 2025 | 94.25% |
| Jun 30, 2025 | 41.49% |
| Mar 31, 2025 | 70.40% |
| Dec 31, 2024 | 61.37% |
| Sep 30, 2024 | 63.12% |
| Jun 30, 2024 | 65.24% |
| Mar 31, 2024 | 26.95% |
| Dec 31, 2023 | 22.04% |
| Sep 30, 2023 | 14.47% |
| Jun 30, 2023 | 18.32% |
| Mar 31, 2023 | -9.91% |
| Dec 31, 2022 | 75.97% |
| Sep 30, 2022 | 96.53% |
| Jun 30, 2022 | 97.13% |
| Mar 31, 2022 | 96.68% |
| Dec 31, 2021 | 91.13% |
| Sep 30, 2021 | 12.05% |